Pre-operative Mocetinostat (MGCD0103) and Durvalumab (MEDI4736) (PRIMED) for Squamous Cell Carcinoma of the Oral Cavity

Stopped The study has been terminated due to a change in internal prioritization and not due to any safety concerns.

Conditions

• Squamous Cell Carcinoma, Head And Neck
• Squamous Cell Carcinoma Mouth
• Resectable Squamous Cell Carcinoma of Oral Cavity

Interventions

• DRUG: Mocetinostat
• BIOLOGICAL: Durvalumab

Sponsor

University Health Network, Toronto

Collaborators

• [object Object]
• [object Object]